CEA、CA19-9、CA50水平与胰腺癌分期和肿瘤大小的关系

Relationship between CEA, CA19-9, and CA50 levels with TNM staging and tumor sizes in patients with pancreatic cancer.

目的探讨血清肿瘤标志物CEA、CA19-9、CA50水平与胰腺癌分期和肿瘤大小的关系。方法分别测定35例胰腺癌和36例慢性胰腺炎患者血清CEA、CA19-9与CA50水平。外科手术和(或)病理学判定TNM分期和肿瘤大小,分析两者之间的关系。结果血清CEA、CA19-9、CA50对胰腺癌诊断的敏感性分别为42%、82%、74%。特异性分别为75%、83%、77%。+期的CA19-9和CA50水平明显高于+期患者(P<0.05),CEA超过正常值者仅见于期以上胰腺癌患者。TS3+TS4组的CEA、CA19-9、CA50水平比TS1+TS2组明显增高(P<0.05)。结论胰腺癌血清CEA、CA19-9、CA50水平与胰腺癌分期和肿瘤大小有一定相关性,对手术前判断胰腺癌的可切除性有一定的参考价值。

Objective To study on the relationship between serum levels of CEA, CA19-9, CA50 with the TNM staging and the tumor sizes in patients with pancreatic cancer. Methods The serum concentrations of CEA. CA19-9, and CA50 were determined in 35 patients with pancreatic cancer and 36 patients with chronic pancreatitis. Pancreatic cancer TNM staging and tumor size were studied by interoperation and/or pathology. The relationship between the tumor marker levels with the TNM staging and tumor size were analyzed. Results The sensitivities of CEA, CA19-9, andCa50in diagnosing the pancreatic cancer were 42%, 82%, and 74%, respectively; and their specificities were 75%, 83%, and 77%, respectively. The levels of CA19-9 and CA50 in patients at stage Ⅲ - Ⅳ were higher than those at stage Ⅰ - Ⅱ （P 〈 0.05）. There was no abnormal CEA found in patients at stage Ⅰ- Ⅱ . The levels of CEA, CA19-9 and CA50 in TS2- TS1 ,groups were higher than those in TS1- TS2 groups （P〈 0.05）. Conclusions SerumCEA, CA19-9, and CA50 levelsare associated with the TNM staging and the tumor sizes in pancreatic cancer patients, which may help to estimate the resectability of pancreatic cancers before operation.